Live Breaking News & Updates on Commercialization committee

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee. Ms Bell joined the Board in August 2022, and is a banking and finance lawyer with 30 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Austral

Monash , South-australia , Australia , United-states , Melbourne , Victoria , London , City-of , United-kingdom , Canada , Singapore , Japan

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progre

Presented Positive Results from Part A of RAMP 201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) at American Society of Clinical Oncology MeetingEstablished Design for RAMP 301 Phase 3 Confirmatory Trial of Avutometinib and Defactinib in Recurrent LGSOCStrengthened Balance.

United-states , American , Dan-calkins , Karin-tollefson , Dan-paterson , Robert-gagnon , Brian-stuglik , Elisa-buffington , Nate-liabraaten , Company-board-of-directors , Raf-and-mek-program , Commercialization-committee

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON (BUSINESS WIRE) Aug 8, 2023

United-states , Massachusetts , Karin-tollefson , Robert-gagnon , Brian-stuglik , Dan-calkins , Elisa-buffington , Dan-paterson , Company-board-of-directors , Commercialization-committee , Amgen , Corporate-communications

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

Brian Stuglik to Retire from CEO Role; Continue to Serve on Company’s Board of Directors

Michael-kauffman , Brian-stuglik , Dan-paterson , Commercialization-committee , Amgen , Drug-administration , Secura-bio-inc , Chugai-pharmaceutical-co-ltd , Company-annual-report-on-form , Exchange-commission , Raf-and-mek-program , Verastem-oncology

BioCentriq Hires David Smith as Vice President of Development

/PRNewswire/ BioCentriq, Inc. a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO) announced today that.

David-smith , Haro-hartounian , Biotechnology-committee , Development-subcommittee , Loughborough-university , Biotechnology-advisory-panel , Commercialization-committee , Gene-therapy-committee , Analytical-method-development , Prnewswire-biocentriq-inc , New-jersey-based , Vice-president